C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 814—Premarket Approval of Medical DevicesSubpart C—Fda Action on a Pma

21 C.F.R. § 814.46 (2026)

Withdrawal of approval of a PMA

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1999–2022 5citing cases
At a glance

Courts have cited this section in 5 opinions since 1999, 1 of them in the last five years.

(a) FDA may issue an order withdrawing approval of a PMA if, from any information available to the agency, FDA determines that:

(1) Any of the grounds under section 515(e)(1) (A)-(G) of the act applies.

(2) Any postapproval requirement imposed by the PMA approval order or by regulation has not been met.

(3) A nonclinical laboratory study that is described in the PMA and that is essential to show that the device is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling, was not conducted in compliance with the good laboratory practice regulations in part 58 and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.

(4) Any clinical investigation involving human subjects described in the PMA, subject to the institutional review board regulations in part 56 of this chapter or informed consent regulations in part 50 of this chapter or GCP referenced in § 814.15(a) and described in § 812.28(a) of this chapter, was not conducted in compliance with those regulations such that the rights or safety of human subjects were not adequately protected or the supporting data were determined to be otherwise unreliable.

(b)(1) FDA may seek advice on scientific matters from any appropriate FDA advisory committee in deciding whether to withdraw approval of a PMA.

(2) FDA may use information other than that submitted by the applicant in deciding whether to withdraw approval of a PMA.

(c) Before issuing an order withdrawing approval of a PMA, FDA will issue the holder of the approved application a notice of opportunity for an informal hearing under part 16.

(d) If the applicant does not request a hearing or if after the part 16 hearing is held the agency decides to proceed with the withdrawal, FDA will issue to the holder of the approved application an order withdrawing approval of the application. The order will be issued under § 814.17, will state each ground for withdrawing approval, and will include a notice of an opportunity for administrative review under section 515(e)(2) of the act.

(e) FDA will give the public notice of an order withdrawing approval of a PMA. The notice will be published in the Federal Register and will state that a detailed summary of information respecting the safety and effectiveness of the device, including information about any adverse effects of the device on health, has been placed on public display and that copies are available upon request. When a notice of withdrawal of approval is published, data and information in the PMA file will be available for public disclosure in accordance with § 814.9.

[51 FR 26364, July 22, 1986, as amended at 83 FR 7387, Feb. 21, 2018]
The 5 cases that cite 21 C.F.R. § 814.46 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENMcLaughlin v. Bayer Corp., 172 F. Supp. 3d 804 (E.D. Pa. 2016).
cites § 814.46 1×cited by 33 cases
Where it cites § 814.46
“” 21 C.F.R. § 814.46 (a). In this case, the Complaint does not allege that the FDA has issued an order withdrawing approval of the Essure PMA or that the FDA has otherwise declared Essureís PMA invalid.”
The case’s holding
A negligence claim against a medical device manufacturer is not preempted if it parallels federal requirements and plausibly alleges duty, breach, causation, and actual damages.
Later courts cite it for
“(1) a duty owed to the plaintiff by the defendant; (2) a breach of that duty; (3) a causal connection between the breach and resulting injury; and (4) actual loss or damages.” · 3 citing courts
2
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 814.46 1×cited by 59 cases
Where it cites § 814.46
“§ 360e(e)(l); 21 C.F.R. § 814.46 (a)(2). 3 B. The PMA Process for the 4004/M Lead The PMA process preceding the FDA’s approval of Medtronic’s 4004/M pacemaker lead was an extensive one.”
The case’s holding
FDA premarket approval of a medical device does not impose an ascertainable federal requirement that preempts state law product liability claims.
Later courts cite it for
“neither the fda's actual review of a device and its supporting information nor the agency's eventual approval of the device imposes any ascertainable requirement upon the device.” · 4 citing courts
3
GREENWoods v. Gliatech, Inc., 218 F. Supp. 2d 802 (W.D. Va. 2002).
cites § 814.46 1×cited by 1 case
Where it cites § 814.46
“§ 360 (e)(1) and 21 C.F.R. 814.46. In this case, Gliatech argues that the MDA preempts Woods’ state law claims.”
4
NO FLAGDains v. Bayer, Inc., No. 5:22-cv-00208 (N.D.N.Y. Nov. 1, 2022).
cites § 814.46 1×cited by 0 casesunknown
Where it cites § 814.46
“2016)); see also 21 C.F.R. § 814.46 (a). Accordingly, Plaintiff has not alleged conduct to underly her failure-to-warn claims “that violates the FDCA,” a necessary prerequisite to avoid express preemption.”
5
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 814.46 1×cited by 0 cases
Where it cites § 814.46
“§ 360e(e)(1); 21 C.F.R. § 814.46 (a)(2).3 to believe the device will be ineffective or present unreasonable safety risks to patients.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199920102022

One bar per year. Tallest: 2 cases in 1999. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
11th Cir.2N.D.N.Y.1E.D. Pa.1W.D. Va.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com